This year marks the seventieth anniversary of Otto Loewi's demonstration of chemical transmission generally and autonomic cholinergic transmission specifically and the fortieth anniversary of John Eccles's proof of the existence of central cholinergic transmission. Following these epochal findings, the subsequent studies of the cholinergic system led to discoveries of similarly important phenomena. This review concerns these phenomena, including chemical structure and molecular biology of cholinergic receptors; electrophysiologic and ionic aspects of pre-and postsynaptic cholinergic events; the quantal expression of cholinergic postsynaptic events and activities of their subunits, the elementary events; and teratology; trophic phenomena; and the clinical aspects of the cholinergic system. This review refers to the history as well as the present status of each of these phenomena; furthermore, it describes briefly the nineteenth-century work with calabar bean, pilocarpine, muscarine, and nicotine, that is, the work performed before the promulgation of the cholinergic era.
author (Karczmar 1986 (Karczmar , 1990 Pepeu 1993) . The last, the VIIIth ICS took place in 1992 in Sainte Adele, Quebec (Cuello 1993) . The participants in the ICSs pioneered much of the modem cholinergic research, and their con tributions at the VIIIth ICS will be referred to.
PRECHOLINERGIC ERA
The cholinergic lore began long before the arrival of the concept of cholinergic transmission. Indeed, the cala bar bean, Ph y sostigma venenosum, was used for centu ries in tribal rites of Western Africa and as an antidote of curare in South America (Karczmar 1970; Holmstedt 1972; Holmstedt et al. 1984) . Subsequently, as the bean Fuhner (1917) and Loewi with Navratil (1926; see Karczmar 1970; Holmstedt 1972 ). Feldberg 1987) . Although Henry Dale (1935) and William Feldberg (1945) 1993-VOL. 9, NO.3 anism for the termination of action of a chemical trans mitter that would be sufficiently rapid to prevent clog ging; however, the rapidity of action of acetyl ChE (AChE) became known in the 1950s helping Eccles's conversion (Karczmar 1991 ). An 
CHOLINERGIC ERA
The next decades provided a rich expansion of this ba sic concept of cholinergic transmission at peripheral and central sites. I will discuss pertinent areas in terms of both their history and their modem status. by Kubo, Peralta, and Haga (Schimerlik 1990 ), led to the defInition of at least &ve subtypes of muscarinic and nicotinic receptors, these subtypes being represented by several variants, as in the case of alpha and beta vari ants of the M2 receptor subtype (Birdsall and Hulme 1983; Schimerlik 1990; Brown 1989; Dahlbom et al. 1986; Kubo et al. 1986; Brown and Masters 1984; Karczmar 1986; Dorje et al. 1991; Sargent 1993; Hulme et al. 1990 ). However, the pharmacologic de&nition of the receptor subtypes was based on in vitro studies of relatively few types of isolated organs, and "none of the tested an tagonists ... and agonists ... showed a marked selec tivity for one subtype over all other subtypes" (Dorje et a1. 1991) .
Muscarinic and Nicotinic Receptors
Of the &ve muscarinic receptor subtypes, Ml and M2 receptors are present in the heart and ganglia, respectively (Mukaiyama et al. 1991) ; these two, as well as M3 and M4 receptors, are present in the CNS, the M1 and the M2 receptors being located at the CNS nerve terminals, as they regulate ACh release (see the sec tion Release of ACh). M3 receptors may be present par ticularly in the hippocampus, as proposed at the VIIIth ICS by Quirion, Pepeu, and their associates (Cuello 1993) .
Some 15 genes control the generation of the mus carinic receptor and its channel (see, for example, Ret tig et a1. 1992). According to a model of the M receptor proposed by Hulme et al. (1990) and Lai, Yamamura, and their associates (Cuello 1993) , there are seven trans membrane helices that are hydrophobic, three extra, and three intracellular domains. This model has to ac count for the functions of the muscarinic receptor and its subtypes, namely, the binding of agonists and an tagonists, the binding and activation of the second mes sengers and G proteins, and the generation of post synaptic currents (see the section Electrophysiological Postsynaptic Aspects of Cholinergic Responses). The tyrosine and aspartic acid residues at the 3rd and 7th transmembrane helix may be particularly involved in ligand binding, while the sequence located at the amino terminal generates the glycosylation needed for the coupling with specifIc G proteins (Schimerlik 1990 ). It must be stressed that several muscarinic receptor sub types may have a common second messenger signal, as they all activate the phosphatidyl inositol cascade with the interaction of appropriate G proteins, depress cAMP generation, and activate phosphokinase C (Schi merlik 1990; see also the section Second Messengers herein); similarly, they all activate several K+ currents (see the section Electrophysiological Aspects). The sub tle differences among the M receptor subtypes with re spect to these various responses were not clearly defined as yet.
Similar work on nicotinic receptors was conducted by Bernard, Lindstrom, Patrick, Salvaterra, Karlin, Noda, Changeux and their associates (Sargent 1993;  Past and Present Cholinergic Studies 183 Barnard et al. 1987) . The cholinergic nicotinic receptors consist of four subunits, alpha, beta, delta, and gamma; the alpha subunit appears twice, and the subunits are organized in a rosette. Furthermore, as shown at the VIIIth ICS by Jim Patrick, Michel Paquet, and others (Cuello 1993) , several variants of these subunits exist. Genetically controlled formation and the organization of the subunits and their variants leads to the diversity and specifIcity of the nicotinic receptor subtypes. Thus, Changeux (1993) posited a complex, multigene "com partmentalized gene expression" mechanism that con trols, via changes in the promoter regions of the genes for the four subunits and in cooperation with trophic factors and kinase activities, the structure, distribution, and ligand specifIcity of the nicotinic receptor subtypes; this mechanism predicates the anisotropic distribution of the nicotinic receptor in the embryonic or denervated muscle, versus its localized distribution in the mature or innervated muscle. The subunits were cloned, and their transmembrane and promoter domains are known (Ratnam et al. 1986; Paquet and Cooper in Cuello 1993; Changeux 1993; Karczmar 1990 ). The second transmem brane domain may constitute the channel pore (Paquet and Cooper in Cuello 1993) . However, the molecular, functional, and structural diff erences between the nico tinic receptor subtypes were not de&ned as yet; for ex ample, it is not understood why the classic alpha bungarotoxin binding is irreversible at the neuromyal junction, reversible in the case of the ganglia and nonex istent at certain central neurons (Chiapinelli and his as sociates in Cuello 1993).
Electrophysiological Postsynaptic Aspects of Cholinergic Synapses
The existence of postsynaptic potentials that result from presynaptic excitation was demonstrated &rst at the motoneuron (Barron and Matthews 1936; Brooks and Eccles 1947) , then at ganglionic and other peripheral synapses, and &nally, in the supraspinal CNS (Eccles 1963; Karczmar 1990) . That changes in ionic permeabil ity and the resulting currents (Hodgkin et al. 1952 ) un derlie the postsynaptic potentials became clear with the advent of the voltage clamp technique (Takeuchi and Takeuchi 1960 ) and the subsequent development of the patch clamp method by the Nobel Prize-awarded team of Neher, Sakmann, and their associates (Hamill et al. 1981) . This then led to the demonstration of nicotinic and muscarinic excitatory postsynaptic potentials and currents (fast and slow EPSPs and EPSCs; Eccles and Libet 1961) . In addition, inhibitory postsynaptic poten tials and currents (IPSPs and IPSCs), whether non cholinergic (today known as aminergic; Lloyd 1947) or cholinergic in nature (Bradley and Wolstencroft 1962) , were demonstrated. More recently, the Kurume-Loyola University team (Katayama and Nishi 1987) observed at the sympathetic ganglia the noncholinergic late slow EPSP; it is generated via the presynaptic activation by a peptidergic neurotransmitter.
The original discovery of Eccles and his associates concerned a nicotinic response at the Renshaw cell; however, the Renshaw cell also exhibits a weak mus carinic response. Although muscarinic, rather than nicotinic, responses predominate in the CNS (Karcz mar 1967), it is apparent today that many central cholinoceptive neurons exhibit either mixed responses, as in the Renshaw cell, or predominantly nicotinic re sponses, as in the case of the thalamus.
In the 1950s and 1970s Fatt, Katz, and Miledi proceeded to "miniaturize" the postsynaptic responses. First, Fatt and Katz (1952) demonstrated the existence, during the quiescent state of the neuromyal postsynap tic membrane, of spontaneously arising miniature MEPPS and MEPCs. The statistical analysis of this phenomenon showed that it reflects the spontaneous, quantal release of ACh and that the evoked release fIres away a packet of 6000 to 8000 quanta; the evoked re sponse is Ca++-dependent (Katz and Miledi 1965) . Morphological counterparts of the electrophysiologi cal phenomena of the miniatures are the synaptic vesi cles as established elegantly by De Robertis (1967), Whit taker (1988, 1992) , and Palay and Palade (1955) . Newer aspects of this matter, namely, cytoplasmic release of ACh, will be discussed subsequently (see the section Release of ACh).
The second phase of "miniaturization" concerned the neuromyal phenomenon of "noise." Many investi gators noticed "noise;" however, only Katz and Miledi (1970) had the serendipity to perceive-and prove via appropriate statistical analysis-that the "noise" is a bio logical phenomenon, as it reflects, in the presence of ACh in the synaptic gap, responses generated by prob ably two molecules of ACh per ionic channel. This phenomenon was termed the elementary event, and the postsynaptic entity involved may be referred to as channel-receptor macromolecule.
The voltage clamp and patch clamp methods, as well as the analysis of the elementary events, provided the ionic and dynamic characteristics of the postsynaptic responses. In the case of the nicotinic channel-recep tor macromolecules, the characteristic fast EPSC is generated by the increase in the Na+ and K+ conduc tance. There are several subtypes of the nicotinic chan nel responses; they depend on the subunit composition and organization of the channel-receptor macro molecule (see the section Receptors), and they differ in the kinetics of their response and binding proper ties. Another factor is Ca + +, as Ca + + may regulate the channel kinetics (Colquhoun et al. 1990; Ogden et al. 1987; Kuba and Nishi 1987) . Altogether, the channels may "show multiple conductance states" (Colquhoun et al. 1990 ), and their response may depend on the state. NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.3 Similarly, the muscarinic responses, the slow EPSP and EPSC, whether at the ganglia or in the CNS, in volve diverse currents that include several types of K + and Ca + + currents; particularly well studied is the voltage-dependent Paul Adam's K + current (M -cur rent; Adams and Brown 1982 ; see also Schimerlik 1990 ). Second-messenger mechanisms mediate these mus carinic responses (see the section Second Messengers), and these mechanisms and the currents that they gener ate are specifIc for the different muscarinic channel receptor macromolecule subtypes. For example, at the VIIIth ICS, Malcolm Caulfield, David Brown, and their associates (Cuello, 1993) related the activation of the M2 and M4 receptors to inhibition of adenylyl cyclase and the generation of Ca + + currents and Ca + + -de pendent K+ currents, whereas the activation of the Ml and the M3 receptors generates the Ca + + -dependent K + current via the stimulation of phosphatidyl inositol cascade and the release of IP3 and inhibits the M-type, voltage-dependent K+ current. These muscarinically evoked currents may not be transmittive in nature; rather, they modulate the excitability of the neurons, as proposed early by Chris Krnjevic (1969;  see the sec tion Interactions, Modulations, and Gene Expression).
Second Messengers
In the 1960s Sutherland, Michell, and the Hokins, and subsequently Paul Greengard, demonstrated that the generation of the current requires intermediaries, termed second messengers (Greengard 1987; Lambert and Nahorski 1990; Berridge 1987) ; to promote perme ability changes, the second messengers cause structural channel-receptor modifIcations via activations of phos phokinases and resulting protein phosphorylation. A number of second messengers are distinguished today, including Lowell Hokin's phosphatidyl inositol cascade, Paul Greengard's several cyclic nucleotides, and Ca++ calmodulin system (Greengard 1987) . The phosphatidyl inositol cascade and diacylglycerol and inositol triphos phate (Berridge 1987 ) and the cyclic guanosine mono phosphate (GMP) respond to muscarinic activation, whereas cyclic adenosine monophosphate (AMP) is sensitive to other agonists or transmitters than choli nomimetics and ACh, such as dopamine. The specifIc second messenger status of the nicotinic response is not clearly established; the evidence presented at the VIII th ICS by Francesca Grassi, Chuan-qui Liu, and their as sociates (Cuello, 1993) suggests that both at the periph ery and in the CNS the nicotinic agonists activate, simi larly to the muscarinic agents, the phosphatidyl inositol cascade and related Ca+ + fluxes (Cuello 1993) . Finally, several guanosine triphosphate-binding proteins (G proteins), whether of heterotrimeric or monomeric (small) type (Yamane and Fung 1993 ) "function as ... additional . . . intermediates in transmembrane signal-ling pathways" (Gilman 1987) , preparing the chan nel-receptor macromolecule for the action of second messengers or otherwise interacting with the latter (Dunlap et al. 1987) . Covalent modifIcations of G pro teins induced by transmitters and resulting phosphory lations, acylations, and so on are "critical in controlling the proper interaction of the G protein with other pro teins, as well with the appropriate membrane compart ments" (Yamane and Fung 1993) . It is important in the present context that the G proteins respond to mus carinic stimulation and specifIc G proteins may recog nize different, specifIc receptor subtypes. Although the phenomena described so far concern the postsynaptic actions, second-messenger mechanisms obtain as well with respect to presynaptic events (see the section) and ACh metabolism (see the section Release of ACh), as well as underlie certain nonsynaptic events, such as postsynaptic desensitization (see the section Interac tions, Modulations and Gene Expression).
Second messenger systems interact; thus, the ac cumulation of cyclic GMP inhibits adenyl cyclase and the generation of cyclic AMP, and the generation of phosphatidyl inositol cascade inhibits the formation of cyclic AMP (Schimerlik 1990 ) and of the Ca + + cal modulin system, as shown at the VIIlth ICS by Michael McKinney (Cuello, 1993) . Many of these inter actions regulate the Ca + + permeability and fluxes. Furthermore, the discoverer of protein kinase C, Yasutomi Nishizuka (1984) proposes that this kinase serves to regulate the interaction between several sec ond messenger systems (Karczmar 1990 ).
Synthesis, Turnover, and Storage of Acetylcholine
There are four components of ACh synthesis. The fIrst component, the generation of acetyl groups via the pyruvate and glucose metabolism and acetyl coenzyme A, was already studied in the 1940s by Mann, Quastel, and von Muralt (Karczmar 1967; Browning 1986; Tu cek 1990) .
The second component concerns choline. Follow ingthe studies of Birks and McIntosh (1961) , the active neuronal uptake of choline, present in the blood via di etary sources as well as in the synaptic cleft following hydrolysis of the released ACh, was considered as a limiting step for both the generation of neuronal cho line and for the synthesis of ACh; the classic results ob tained by the Canadian investigators could not have been gathered without the previous development, by Fred Schueller and John Long, of hemicholinium, the specifIc inhibitor of the active transport of choline (Long 1963) . Subsequently, the work of Bremer, Wecker, Greenberg, Wurtman, Blusztajn, Loffelholz, Ansell, and Tucek (Ansell and Spanner 1979; Tucek 1990 ) related the availability of choline and the synthesis of ACh to neuronal phospholipid metabolism and, par-
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ticularly, that of phosphatidylcholine. How important the brain phospholipid metabolism is for the genera tion of choline is not clear at present (Tucek 1990 ); Ri chard Wurtman (Ulus et al. 1989; Nitsch et al. 1992b) opined that this metabolism is indeed very important and that, under certain stress circumstances, such as those occurring in SDAT, its obligatory maintenance may require "autocannibalism" of cholinergic neurons.
The third component of ACh synthesis is the acet ylation of choline, mediated by choline acetyl transfer ase (CAT; E.C. 2.3.1.6.), an enzyme discovered by David Nachmansohn in the 1940s (with Machado). With the advent of molecular biology methods, the identi ncation of the CAT gene in Drosophila (Greenspan 1980) and cloning and development of monoclonal CAT an tibodies (Levey et al. 1981) , the story of CAT became complex, as a number of transcriptional sites and exons were identifIed in animals and man (Strauss and his associates in Cuello 1993) . For example, the 5' flanking domain of CAT regulates on the transcriptional level the appearance of CAT in specifIc neurons as well as its ontogenesis, as described at the VIIlth ICS by Paul Salvaterra and his associates (1993) . Transcriptional mechanisms also control the trophic effect of nerve growth factor (NGF) on CAT (see Bejanin, Mallet, and their associates in Cuello 1993; see also the section Tro phic Factors, herein), and the compartmentalization of CAT within the cytosol and the membrane and the shifts between these two sites also contribute to the regulation of ACh synthesis (Rylett 1993) . This new evi dence suggests that CAT, rather than choline, is the limiting step in ACh synthesis (Rylett 1993) . It must be added that second messengers, such as cyclic nucleo tides and retinoic acid, activate ACh synthesis via their control of CAT activity and, perhaps, phospholipid me tabolism (Blusztajn et al. 1993) .
The fourth component of ACh anabolism is its ac cumulation and storage prior to its synaptic release, whether in the synaptic vesicles, according to the clas sical view on the matter (Whittaker 1990 (Whittaker , 1992 or in the cytoplasm, as related to the cytoplasmic release of ACh (see the section Release of ACh). The vesicles are engaged in the process of recycling, as, following the vesicular uptake of ACh, the loaded vesicles move to the nerve terminal, fuse with the membrane, and re lease ACh, the empty vesicles coursing away from the membrane (Whittaker 1992) . The vesicular uptake may include a high-and low-affinity mechanism, possibly characterizing the vesicular populations concerned with the readily releasable ACh and reserve ACh, respec tively, as suggested at the VIIlth ICS by Brian Collier and his associates (Cuello 1993) . Vesamicol is a specifIc inhibitor of the active, high-affinity vesicular uptake of ACh, acting at a proteoglycan receptor site, as shown at the VIIlth ICS by Stanley Parsons and his associates (Cuello 1993 ).
In the 1970s Steve (B. B.) Brodie and Erminio Costa stated that the turnover of a transmitter, that is, the steady state resulting from the dynamics of transmit ter synthesis, uptake, hydrolysis, and release, is func tionally more important than the levels of the transmit ter, and Costa, Neff, Karlen, Hanin, Holmstedt, Jenden, and others developed the methodology needed for the measurement of ACh turnover (see, for example, Karlen et al. 1986 ). As pointed out at the VIIIth ICS by Stanislas Tucek, Don J enden, Konrad Loffelholz, Os car Scremin, and others (Cuello 1993) , ACh turnover in the brain depends on the phospholipid metabolism and the generation and availability of several ACh precursors; the active, phosphorylation-dependent cho line uptake across the blood-brain barrier; the arteri ovenous difference in choline concentration that implies that there is a continuous choline loss from the brain; and such conditions as apnea and ischemia.
Cholinesterases
After Dale and Loewi established the existence and the role of ChEs (Augustinsson 1948) , Stedman et al. (1932) and Mendel and Rudney (1943) described the "true," or "specifIc" or rbc, ChE and the "pseudo," or serum, ChE; today, these two forms are referred to as AChE and butyryl ChE (BuChE; see Karczmar 1967 Karczmar , 1970 . Ac tually, we deal here with families of genetically diverse enzymes and isozymes rather than with two enzymes, as frrst demonstrated with respect to BuChEs by Werner Kalow (1959) .
AChE is the synaptic enzyme, the rapidity of its ac tion making the transmission possible. On the other hand, BuChE participates in the function of the smooth muscle, whether of the intestine (Koelle 1963) or of the trachea (Adler and Filbert 1990) . BuChE probably does not control the pertinent transmission but acts as a "safety valve" for the parasympathetic system (Adler and Filbert 1990) . These enzymes are also present at nonneuronal sites, sometimes at high concentrations, including the formed elements of blood and ephemeral organs, such as the placenta.
Further work with, particularly, organophospho rus anti-ChEs (see the section Anticholinesterases) and the analysis of the aminoacids abutting immediately on the phosphorylation sites of AChE treated with these drugs led to establishing the role of serine and imida zole noiety in the catalytic function of AChE (Usdin 1970) . The subsequent research culminated with the description by Hermona Soreq and her associates of the human genome involved in the synthesis of several forms of AChE and BuChE (Soreq and Zakut 1990) and with Jean Massoulie's defInition of physically and bind ingwise different variants of AChE (Massoulie and Bon 1982; Sussman et al. 1991) . As discussed at the VIIIth ICS by Hermona Soreq (Cuello 1993 ) the human genes for AChE and BuChE were mapped to chromosomes NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.3 22 and 26, respectively; these sites are subject to evolu tionary and environmental mutagenesis, via exposure to anti-ChEs, and as result of such diseases as leuke mia and motor activity (Gissiger and his associates in Cuello 1993). The six or more molecular forms of AChE distinguished by Jean Massoulie and his associates (Massoulie et al. 1993a, b) are generated by the H and T subunits, and they include symmetric, globular, whether amphiphilic or nonamphiphilic, forms on the one hand and asymmetric, collagen tailed forms on the other; these forms differ with regard to their cellular location and attachment to the cell membranes. Fur thermore, Massoulie and Sussman (Sussman et al. 1991; Massoulie et al. 1993b ) combined this approach with crystalographic determination to propose that there is within AChE "a deep and narrow gorge .. . for binding and hydrolyzing ACh ... lined with the rings of 14 aromatic aminoacid residues," the quater nary group of ACh ligating the indole ring and the ac tive site for hydrolysis of ACh being a serine-histarnine glutamate triad, a conclusion not too different from that reached in the 1960s. Finally, Massoulie found that anti ChEs produce specifIc conformational changes in the gorge.
It became apparent in the 1960s that the classical notion of the unique association of AChE with the ter mination of cholinergic transmission may not be cor rect, as suggested by the presence of ChEs in non neuronal tissues, including the preneurogenetic embryo (Koelle 1963; Karczmar 1963a ; see also the sec tion Cholinergic Ontogeny and Teratology). A relevant evidence concerns the novel phenomenon of the release of AChE that occurs upon physiological or presynaptic stimulation not only from cholinergic but also from the noncholinergic brain sites and the fInding that ex ogenously applied AChE hyperpolarizes the dopamin ergic neurons, acts on the auto-and heteroreceptive nerve terminal sites, and exhibits postsynaptic effects (Appleyard 1992) .
Anticholinesterases
Currently, derivatives of physostigmine and other anti-ChEs are among most the widely used drugs, whether clinically (see the section Clinical Aspects) or in pharmacological analysis.
Following its purifIcation, the structure of phys ostigmine was established in the 1910s and 1920s by Polonowski with Nitzburg and Stedman with Barger (Karczmar 1970; Holmstedt 1972) . Following the syn thesis of physostigmine, neostigmine, and some of thei r analogs by my late Oak Park, illinois, neighbor, Percy Julian (see Karczmar 1970) , countless derivatives of this carbamate anti-ChE were obtained, including many bisquaternaries, such as the very potent oxamides, and "simplifIed" compounds such as the hydroxyaniliniurns (represented by edrophonium, a diagnostic agent for myasthenia; see Long 1963) . Although the duration of anti-ChE action of these compounds varies greatly, from just minutes or under 1 hour in the case of edropho nium and physostigmine, respectively, and several hours in that of such oxamides as ambenonium, all these carbamate and related compounds are classified together as reversible anti-ChEs; in their case, sponta neous or enzymic hydrolysis yields an unchanged in hibitor and unchanged ChE. (For the new reversible anti-ChEs, see the section Clinical Aspects.)
Organophosphorus (OP) anti-ChEs were frrst syn th esized in the middle of the last century, in France and Russia, as De Clermont and Moschnine developed tetraethylpyrophosphate (Holmstedt 1959 (Holmstedt , 1963 Karcz mar 1970) . Subsequent, vigorous synthesis of a multi tude of OP drugs was carried out in Germany, as their toxic activity against parasites as well as animals was observed by Lange, Schrader, Krueger, and other Ger man investigators (Holmstedt 1963) . Their war gas potential was exploited at a large factory complex in Du hernfurt, East Germany, and Koelle (1981) contends that the negotiations after the Second World War be tween Churchill and Roosevelt on the one hand and Stalin on the other as to the exact position of the border between Poland and East Germany were long and diffI cult because Duhernfurt and its war gas factory be came the bone of contention.
As the German war gas effort became known to the Allies in the 1930s, parallel research was initiated and carr ied out by the British team led by Lord Adrian and Saunders at Cambridge and elsewhere and the USA team at Edgewood Arsenal. This effort provided train ing to many prominent investigators such as, in the case of USA, Koelle, Gilman, Riker, Bodansky, Comroe and Wills (Koelle and Gilman 1949; Karczmar 1970) . Among the well-known war gases that resulted from the Ger man and Allied war effort are Tabun, Soman, and Sa rin; the drug most frequently used in basic research is dii sopropyl fluorophosphonate (DFP).
Contrary to the reversible inhibitors, the OP anti ChEs cause, following "aging," that is, the allosteric change in the combination product, irreversible inhi bition; indeed, the original substances, that is, the OP drug and the ChE, cannot be recovered after "aging. " Limitless substitution are possible with respect to the parent substance, the phosphoric acid. These substi tutions include inorganic ions such as halogens, and organic radicals such as CN; furthermore, sulfur may be substituted for the oxygen of the phosporic acid moi ety (Holmstedt 1959 (Holmstedt , 1963 . The substituted compounds include numerous insecticides such as ethoxy-4-nitro phenoxy-phenyl-phosphine sulfIde (EPN), anthelmin thies, and drugs potentially l.lseful in SDAT therapy, such as metriphonate.
The anti-ChE effect depends on the reaction of the catalytic or esteratic site of ChE, which includes serine and one or more hydrophobic sites (Ishihara et al. 1991) Past and Present Cholinergic Studies 187 with carbamate or related moiety of the reversible in hibitors and its phosphorylation in the case of the OP compounds. Quaternary grouping, when present, helps in the ligand action, as it reacts with the anionic site of the ChE molecule. Anti-ChEs differ with respect to their potency as inhibitors of AChE and BuChEs; this difference may be quite extensive, as in the case of the oxamide, ambenonium, and DFP, which inhibit preponderantly AChE and BuChE, respectively. Yet, even these compounds are not entirely specific, and most anti-ChEs exert signifIcant actions on both en zymes. Furthermore, the anti-ChEs diff er in their effects on the subtypes of ChEs that we described, and the mechanisms underlying these diff erences are not clear.
Originally, it was thought that particularly OP anti ChEs, such as DFP, exert effects solely dependent on their inhibition of ChEs and the resulting accumulation of ACh; initially, these effects lead to the facilitation of cholinergic transmission sites, and then undue ACh ac cumulation blocks the sites, whether by "clogging" or desensitization (see the section Interactions, Modula tions, and Gene Expression). This latter action results in anti-ChE toxicity, particularly respiratory failure (due to both central and peripheral block of the pertinent cholinergic transmission) and cardiovascular collapse. Yet, "direct" actions of anti-ChEs were already de scribed in the 1940s (Karczmar 1967 (Karczmar , 1970 . Today, con vincing evidence shows that anti-ChEs, particularly of the OP type, exert a number of "direct" postsynaptic actions on the receptor-channel macromolecule and/ or its channel component (Albuquerque et al. 1984 ) and on carbohydrate metabolism; they also cause morpho logical, pathological (including muscle myopathies and neurotoxicity), and teratological actions (Karczmar 1984 (Karczmar , 1985 ; see also the subsection Cholinergic Ontogeny and Teratology).
The delayed neurotoxicity, noticed for the frrst time in 1896 (Davies 1963) , affects both peripheral and cen tral axons, such as those of the selected spinal and supraspinal fasciculi; it is followed by demyelination. Many OP agents (such as Mipafox and DFP), exert this effect at large doses; phosphocreosote and triortho-tolyl phosphate (TOCP) are particularly neurotoxic, although they have a relatively weak anti-ChE action; their effect seems to be linked with the inhibition of a poorly defIned enzyme, referred to as neurotoxic esterase (Johnson 1987; Abou-Donia and Lapadoula 1990) .
Of particular interest are the delayed or chronic be havioral and electroencephalogram (EEG) actions (recorded in animals as well as in man) in industrial workers exposed to OP agents or volunteers used in the 1940s in pertinent research; these include night mares and mood changes that persist for months or years (see Karczmar 1984) .
The antidoting of the anti-ChE toxicity is important in view of the worldwide use of OP drugs as anthel minthics and insecticides, and their potential use as war gases. Today, a combined prophylactic or antidotal treatment is employed that includes atropine or other atropinics to relieve or prevent central symptoms, in cluding respiratory failure, reversible anti-ChE com pounds that protect ChEs, and the oximes that work as reactivators of phosphorylated AChE, provided the latter did not have the time to "age." These interesting compounds, developed in the 1950s by Irving Wilson and David Nachmansohn (Karczmar 1970) force the re lease of the phosphoryl moiety of the blocked enzyme; the most potent oximes are quaternary in nature, hence they cannot antagonize the central OP toxicity, the newer tertiary oximes being of doubtful efficacy.
Release of ACh
The release of ACh was demonstrated in the 1930s by Dale, Feldberg, and Vogt (Feldberg 1987; Karczmar 1967) for peripheral cholinergic synapses; this con stituted an important component of the proof of the cholinergicity of the pertinent synapses. It is very diffi cult to demonstrate the release of ACh from specific central synapses; using an ingenious micro dialysis pro cedure to measure ACh outflow from selected brain area, Giancarlo Pepeu (Pepeu et al. 1990; Pepeu, 1993) came as near to this demonstration as possible.
The Ca + + dependence of ACh release at the pe riphery was already referred to; the validity of this de pendence in the CNS was confmned subsequently by Pepeu and others. The activation of protein kinase C, which abounds in the nerve terminals, appears to be necessary for ACh release via its regulation of Ca + + channels (Kaczmarek 1987) . Several specific proteins present in the vesicles, such as synaptobrevin, and the presynaptic plasma membrane may contribute to the release via targeting the vesicles at the release sites and via other mechanisms (Betz 1992) . Another protein that may be involved is synapsin; Paul Greengard and his associates (Greengard 1987) presented evidence that this protein regulates, via phosphorylations and de phosphorylations and additional second messenger mechanisms, ACh release; a specific non-ACh trans mitter may be involved in the synapsin activation, al though this and other aspects of Greengard's hypoth esis are controversial (Karczmar 1990 ). Other proteins, the so-called neurotransmitter transporters that are involved in blocking neurotransmitter uptake, were identified for GABA and catecholamines. Although some reuptake of ACh occurs, this is minimal compared to the uptake of choline, and transporters for either ACh or choline have not been identifIed as yet.
The vesicular hypothesis of the release of ACh, based on the concepts of Katz, Miledi, DeRobertis, and, particularly, Victor Whittaker, was already described. Is this hypothesis an absolute tenet today? Actually, the cytoplasmic, vesicle-independent release of ACh was well documented by Maurice Israel, Yves Dunant, and N. Morel; they used the elegant, ultrarapid and ultrasensitive choline oxidase chemoluminescent method for ACh measurement, as well as cytoplasmal proteoliposomal membrane complexes endowed with a "reconstituted ACh release mechanism" (Israel and Morel 1990; see however, Whittaker 1992 ). This release is mediated by a nerve terminal proteolipid, the medi atophore; the Kd subunit of the mediatophore was com pletely sequenced. The essential features of the non vesicular release of ACh, such as Ca + + dependence, were preserved in the proteoliposomal model as well as in the oocyte loaded with mediatophore mRNA and the Kd protein. Furthermore, as shown at the VIIIth ICS by Dunant, Cavalli, and their associates (Cuello 1993) , in the primed oocyte the rate of ACh release and the expression of the mediatophore were decreased in parallel by the antisense probes.
The auto-and heteroreceptor-mediated regulation of ACh release was fIrst described in the 1950s. Koelle, Nishi, Szerb, and Polak (Karczmar 1990; Schuetze and Role 1987 ) demonstrated muscarinic and nicotinic effects on cholinergic nerve terminals and ACh release in the ganglia and CNS that are mediated by choliner gic muscarinic and nicotinic presynaptic auto receptors; these fIndings were confmned recently by means of ap propriate antibodies (see for example, Dunant and Cavalli in Cuello 1993) . The heteroregulation by ACh and cholinomimetics of the release of nonACh trans mitters, posited fIrst by Loffelholz and Muscholl (Loffel holz et al. 1967 ) for noradrenergic transmission, obtains as well for other transmitters. Whether in the case of the auto-or heteroregulation, both facilitatory and in hibitory mechanisms may occur, although the latter are more frequent.
The reverse takes place as well, as shown for the fIrst time by Amadeo Marrazzi (Karczmar 1967 ) with respect to catecholamines. Besides catecholamines, in dolearnine, arninoacid, and polypeptide transmitters including galanin and its analogs (see Barfai and Con solo in Cuello 1993) -as well as prostaglandins and, as shown by Remi Quirion at the VIIIth ICS (Cuello 1993) , interleukins affect the release of ACh. Again, inhibi tion of release is the prevalent phenomenon; opposite effects may occur at different sites and at different con centrations of the agents in question, as shown at the VIIIth ICS by Shirati, Consolo, and their colleagues (Cuello 1993) .
As is well known, neurotoxins derived from vari ous sources, such as amphibian skin, snake venoms, insects, and bacteria, also affect ACh release. These pro teins include the botulinum (clostridial) toxin that in hibits the ACh release and black spider venom that causes a massive release of ACh. These substances act not on the cholinergic nerve terminal receptors but on receptors concerned with Ca + + fluxes, microtubule systems of the terminals, and/or the synaptosomal and vesicular membranes (Dolly 1993) .
Central Cholinergic Pathways
Dale and Feldberg (Feldberg 1945) (he lived, however, to describe vividly the mental and functional effects of the ingestion), and Bezold and Gotz in 1867 and others described the respiratory and con vulsive effects of either the purifIed bean extract or phys ostigmine (Karczmar 1970; Holmstedt 1972) . In the 1940s studies of conditioning (Funderburk and Case 1947) , and multiple other functions were initiated, including those dependent on the hypothalamus, such as appetitive effects and thermocontrol (Myers 1974 ).
Subsequently, Himwich, Bovet, Oliverio, JOllvet, Deutsch, Drachman, Stein, Russel, and others demon strated the effects of atropinics, anti-ChEs, and choliner gic agonists and antagonists (whether given directly into localized CNS sites or given systemically in the case of drugs capable of crossing the blood-brain barrier) on learning and memory, arousal and sleep, nociception, aggression, fear, addiction, and reward-punishment be havior (Waser 1975; Karczmar 1967 Karczmar , 1970 Karczmar , 1981 Karczmar , 1990 Hintgen and Aprison 1976) . The cholinergic correlates of these functions and behaviors were established not only by the nature of the drugs employed but also by the presence of the cholinergic pathways in the perti nent brain areas and the demonstration of the release of ACh following either the stimulation of these path ways or the evocation of these functions (Pepeu 1993) .
Particularly interesting (see the section Clinical
Aspects) was the demonstration that anti-ChEs and cholinergic agonists facilitate a number of condition ing paradigms while atropinics block learning, condi tioning, and memory, both in animals and man; thus, Drachman (1978) showed quantitatively that, in man, atropinic amnesia is a close equivalent of senescent amnesia.
It must be stressed that no behavior is a one transmitter affair, and catecholaminergic, serotonergic, and other systems participate in the functions listed; yet, frequently, the cholinergic system constitutes the signifIcant correlate. This is true for learning, memory, and aggression; there are many forms of aggression, such as predatory and emotional aggression, and the aggression related to the defense of the pups or habi tat, and so on, and certain transmitters affect one or an other of these aggressions, yet only the cholinergic sys tem regulates all these forms (Karczmar 1978; Eichelman 1990 ). Altogether, there is no measurable animal or hu man behavior that does not exhibit cholinergic corre lates.
The EEG and related phenomena merit special com ment. That the cholinergic system evokes EEG desyn chronization and contributes signifIcantly to the Ma gun-Moruzzi EEG and behavioral arousal and to the function of the reticular formation was demonstrated in the 1950s by Wescoe, Bremer, Chatonnet, Himwich, Rinaldi, Domino, Longo, and others (Karczmar 1967 ).
Yet, subsequent research of the Killams, Bures, Gang loff, and, particularly, Abraham Wikler (Karczmar 1967) showed that the cholinergic EEG arousal was not ac companied by behavioral arousal, there being a "di vorce" between these two phenomena. This paradox was resolved, as it became apparent via the power spec trum analysis of the EEG that the cholinergic EEG arousal differs from the EEG arousal accompanying be havioral wakefulness (Karczmar 1979 
Cholinergic Ontogeny and Teratology
In the 1930s such early investigators of the ontogeny of the cholinergic system as Nachmansohn, Young strom, and Bacq (Karczmar 1963a) attempted to prove the cholinergicity of the nervous system by demonstrat ing that AChE appears at the time of the ontogenetic onset of such functions as motility. An unforeseen phenomenon that was discovered at that time was that AChE and, as shown subsequently, ACh and CAT arise, whether in vertebrate or invertebrate ontogene sis, precociously, that is, before neurogenesis (Karcz mar 1963a; Buznikov 1984) . In fact, cholinergic compo nents may appear in high concentrations in the two-cell stage or, even, in the unfertilized egg. This precocious appearance of the cholinergic components relates to their presence at noncholinergic sites. Taken together, these phenomena suggest that the cholinergic system must play a nontransmittive role, and its trophic role was suggested early (Karczmar 1946 (Karczmar , 1963a ) .
In the course of ontogenesis the components of the cholinergic system increase signifIcantly in concentra tion or activity at the onset of neurogenesis as well as subsequently; in fact, this increase continues postna tally, at least in animals. Yet, there are periods of dimi nution of cholinergic components, in parallel with the decrease in the number of nonneuronal cells in the case of the prenervous ontogeny or with the characteristic neuronal "death" that occurs during neurogenesis.
The cholinergic neurogenesis is characterized by a nonparallel development of CAT, ChEs, ACh synthe sis, and cholinergic receptor-channel macromolecules (Karczmar 1963a, b; Rotundo 1987; Layer et al. 1987; see, however, Giacobini 1986 ) . Thus, the cholinergi c receptors bind early the ligands and yet are "silent" wi th respect to ACh and cholinomimetics, whereas CAT and ACh precede this event . The advent of their cholinocep tivity occurs prior to their morphological maturity, and, following the initiation of cholinoceptivity, the recep tors change their structure, subunit composition, chan nel characteristics and kinetics, fluidity, and so on, both prenatally and postnatally, as their response assumes mature kinetics (Salpeter 1987; Giacobini 1986; Fam brough 1976) .
It is important in this context to note the choliner gic effects on development. Cholinergic agonists and antagonists cause in several animal species embryoni c death or teratology; it is interesting that these effects were observed with pilocarpine by Matthews and Sollman as early as in 1902! The teratological effects may range from changes in ''body proportions" and in the skeleton to micromelia, syndactilism, and phocomelia (Karczmar 1963b; Karczmar et al. 1973) ; most of these effects were obtained with anti-ChEs, including the OP drugs. NEUROPSYCHOPHARMACOLOGY 1993-VOL . 9, NO. 3 Only a few data are available about the teratologi cal action of cholinergic agonists or antagonists in man.
Controversial evidence was presented in the course of legal proceedings with respect to antihistaminic drugs that, although they are essentially antihistaminics, exert also atropinic effects; these drugs, such as doxylamine, are used in man as antiemetics or analgesics. Consid erable controversy surrounds pertinent studies carried out in primates (Hendrickx et al. 1982; McBride 1985) .
Trophic Phenomena
The matter of trophic factors relates to development, 
Interactions, Modulations, and Gene Expression
A cholinergic system does not exist in a vacuum; it is subject to interactions with and modulations by other bioactive, endogenous substances. It is easy to illustrate this interaction by demonstrating that cholinergic ago nists and antagonists affect the levels and turnover of other transmitters, including catecholamine, indole amines, and aminoacids (Karczmar 1978) . This should be expected, as the cholinergic radiations abut on the other transmitter systems, and it was shown early by Eccles (1963) that such couplings result in vectoral in teractions between the pertinent responses, such as the E and I potentials. Thus, it was shown directly for the nigrostriatal and brainstem areas that specifIc excitation of cholinergic neurons affects catecholaminergic or GABAeric neurons of these areas (Straughan and James 1979) . That every central function or behavior is affected by several transmitter systems and their agonists and antagonists also illustrates this notion (Karczmar 1978) .
Modulations constitute a more subtle example of the interaction between the cholinergic and other sys tems. The term modulation, defined first by Kyo Ko ketsu, Les Blaber, and this author (Karczmar et al. 1972; Karczmar 1990; Akasu et al. 1981) Thesleff (1955) and Karczmar and Howard (1955) . The effect in question was desensitization or receptor inac tivation arising from prolonged application of depolar izers, including ACh, to the motor endplate . The op posite process is that of sensitization (Karczmar and Howard 1955; Karczmar 1957 Karczmar , 1987 . Both processes are due to an allosteric receptor change (Akasu et al. 1981);  in the case of desensitization, this change may be medi ated by the activation of one or more kinases by a non cholinergic transmitter (Greengard 1987; see, however, Colquhoun et al. 1990 ).
The drugs acting as postsynaptic modulators, such as NaF and the oxamide WIN8078, facilitate transmis sion, including that of OP-bound synapses, even after the process of aging has intervened, and, uniquely, an tagonize both the competitive and depolarizing neu romyal blockers (Karczmar 1957) .
Postsynaptic modulation may also result from the so-called transsynaptic regulation, that is, postsynap tic activation of protein synthesis. This concept dates to the demonstration by Holger Hyden (1972) of learn ing-dependent activation of specific mRNAs and pro teins in pertinent brain parts; subsequently, this pro cess was shown to occur upon presynaptic stimulation (Axelrod 1971; Costa and Guidotti 1978) . Perhaps the ultimate expression of trans synaptic regulation and the resulting modulation of postsynaptic responses is con stituted by genetic induction; Hyden mentioned this phenomenon, without being able to demonstrate it directly, to explain his findings. The genetic induction may take form of either immediate, early, or late gene expression (Menetrey et al. 1989 ) and may be gener ated by transmitters and physiologic stimuli (Shen et al. 1992 ). Levin et al. 1990; . (Peters and Levin 1979; Thal 1991) and as its effectiveness appeared dubious, the second generation of anti-ChEs were developed. These include physostigmine and pyridine derivatives, such as hep tylphysostigmine and the huperzines; tetrahydroami noacridine (tacrine, THA), today the most intensely used anti-ChE; and even OP drugs, such as metrifonate (Giacobini 1991) . It is interesting that, like physostig-mine, the huperzines are naturally occurring com pounds, their source being the Chinese clubmoss (Gia cobini 1991; Hanin et al. 1991) . The aim was to obtain compounds with longer action, better penetration into the eNS, and more specifIc anti-AChE action, and this aim persists, as still newer anti-ChEs are being devel oped, such as the Sandoz drugs.
Some investigators contend that anti-ChEs delay the progress of SOAT; however, the consensus seems to be that, even with the newest anti-ChEs the results are limited: Certain aspects of memory seem to benefIt to a limited degree, and there is little if any restoration of other aspects of cognition and social, domestic, or professional function. Theoretically, several reasons may underlie this situation. First, anti-ChEs facilitate the function of existing cholinergic neurons; yet, in late SDAT very few such neurons may remain intact; sec ond, anti-ChEs exhibit many cholinergic and non cholinergic effects that are counterproductive in this context, the "therapeutic window" of anti-ChE therapy is narrow, and centrally effective doses of these com pounds may not be achievable as they would produce untoward side effects (Karczmar and Dun 1988) . More importantly, the nature of SOAT as perceived today should limit the expectations of success that may be achieved with anti-ChEs. In a nutshell, SOAT appears to be a multifactorial condition that embraces diffuse degenerative changes of the neuronal cytoskeleton, in cluding undue beta-amyloid synthesis and formation of senile plaques, neurofIbrillatory tangles and heavy protein; these changes affect cholinergic and non cholinergic neurons and, besides ACh, other transmit ters and peptides. The related problem is that many an imal models used today concern more the "cholinergic hypothesis" of SOA T than the actual disease, as these models rely on chemical or surgical damage inflicted on the cholinergic neurons; in fact, these models differ from SOAT in several respects (Karczmar 1991) .
As any area of the cholinergic fIeld, this particular area is not devoid of controversies. Contrary to the sense of the views described, there is sporadic infor mation that some of the cholinergic animal models of SDAT may exhibit abnormal amyloid formation (Wal lace et al. 1991) ; also, Richard Wurtman and his associ ates (Nitsch et al. 1992a ) claim that cholinergic therapy may prevent the formation of amyloid depositions. Al together, it is this author's present belief that the ani mal and tissue culture models that rely on molecular engineering or other means to evoke the pertinent cytoskeleton changes (see, for example, Price 1993) ap pear to be more appropriate in the present context than the models based on the cholinergic hypothesis of SDAT. It must be noted that the arguments raised here militate not only against the effectiveness in SOAT of anti-ChEs but against the effectiveness of cholinergic agonists and precursors as well; yet considerable de- Past and Present Cholinergic Studies 193 velopment of these compounds continues, as discussed at the VIIIth ICS (see for example, Davis 1993) .
It must be stressed that the story of the clinical use and effectiveness of cholinergic and anticholinergic drugs has barely begun. In this context, certain issues raised by Don Jenden (1990) are pertinent. Jenden stresses that, as many subtypes of cholinergic recep tors are being identifIed and their localization is becom ing better known, appropriate synthesis of specifIc receptor agonists and antagonists will yield better ther apeutic agents that would, it is hoped, be devoid of del eterious side actions; as important, the interplay be tween intrinsic efficacy and tissue distribution of the compounds in question will dictate the specifIcity and organ or tissue localization of these compounds, hence, the therapeutic specifIcity of their action .
ENVOI
The cholinergic studies that brought to us so many cru cial fIndings in the past, will indubitably bring new, no less crucial fIndings in the future. These will lead to a better understanding of the second messenger and G proteins cascade as activated by the cholinergic system, and of its relationship to specifIc, cholinergically engen dered currents; better defInition of and addition to the present list of the nicotinic and muscarinic receptors; clarifIcation of the interaction between the cholinergic and other systems and of the modulatory and early gene processes; further identifIcation of trophic factors and their role in the ontogenesis and maintenance of the cholinergic system; increased availability of new syn thetic therapeutic agents; and, above all, specifIc de scriptions of the molecular biology of the components of the cholinergic system and of its ontogeny. However, to use the facts related to these and other factors for the "prediction of the postsynaptic ... cholinergic . . . outcome ... requires a computer program which does not begin to exist"; predicting the "ultimate ... be havioral outcome may be beyond any potential com puter capacity" (Karczmar 1993) , as the system in ques tion is complex enough to be, on the basis of Goedel's theorem and the theory of chaos, never fully consis tent and never predictable.
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